Trial · NCT01841736
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Arm I (Pazopanib Hydrochloride) | 11.6 | 80% Confidence Interval 11.0 to 13.0 | months | |
| Progression-free Survival (PFS) | Arm II (Placebo) | 8.5 | 80% Confidence Interval 5.8 to 8.9 | months | |
| Best Response | Arm I (Pazopanib Hydrochloride) | Partial Response | 2 | Participants | |
| Best Response | Arm II (Placebo) | Partial Response | 0 | Participants | |
| Best Response | Arm I (Pazopanib Hydrochloride) | Stable Disease | 70 | Participants | |
| Best Response | Arm II (Placebo) | Stable Disease | 54 | Participants | |
| Best Response | Arm I (Pazopanib Hydrochloride) | Progressive Disease | 4 | Participants | |
| Best Response | Arm II (Placebo) | Progressive Disease | 14 | Participants | |
| Best Response | Arm I (Pazopanib Hydrochloride) | Not Evaluable | 21 | Participants | |
| Best Response | Arm II (Placebo) | Not Evaluable | 6 | Participants | |
| Overall Survival | Arm I (Pazopanib Hydrochloride) | 41.3 | 80% Confidence Interval 31.9 to 44.8 | months | |
| Overall Survival | Arm II (Placebo) | 42.4 | 80% Confidence Interval 29.7 to 50.8 | months | |
| Duration of Response for the Subset of Patients With a Confirmed Complete Response or Partial Response | Arm I (Pazopanib Hydrochloride) | 11.9 | 95% Confidence Interval 9.8 to NA | months | |
| Duration of Response for the Subset of Patients With a Confirmed Complete Response or Partial Response | Arm II (Placebo) | 13.8 | 95% Confidence Interval NA to NA | months | |
| Time to Treatment Failure | Arm I (Pazopanib Hydrochloride) | 8.5 | Full Range 0.9 to 53.8 | months | |
| Time to Treatment Failure | Arm II (Placebo) | 8.6 | Full Range 0.3 to 48.0 | months | |
| Time to Second Progression for Patients Who Crossover From Placebo to Active Therapy | Placebo Crossover | 12.1 | 95% Confidence Interval 5.9 to 19.5 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01841736/results